People with severe TB know little about side effects: Study

Greater awareness about tuberculosis drugs and their side effects can help patients cope with their condition better and reduce the “default rate”, the number of people who quit their treatment midway, a study has revealed.

Doctors from Sewree TB Hospital conducted the study after collaborating with the Indian Council of Medical Research. Sixty-two patients suffering from multi-drug-resistant (MDR) strain of the disease were interviewed and nearly half of them did not have any knowledge about the side effects of their medications or the ways to tackle them.

The drugs for battling MDR TB can cause vomiting, rashes, joint pains, mood changes, ringing in the ears, vision problems and flu-like symptoms, making it extremely difficult for the patients to function normally. Doctors refer to the effects as adverse drug reactions. Often, people give up the treatment, hoping they will feel better. But this only complicates the issue: breaks in treatment increase the chances of developing a tougher strain.

There are also instances where patients don’t know that there are medicines that can help them manage the side effects.

The study, thought to be first of its kind, suggested extensive and regular counselling of patients to deal with all types of problems to the TB medications.

MDR TB is caused by the bacillus Mycobacterium tuberculosis strain, which is resistant to the first-line drugs such as rifampicin and isoniazid. Instead of the regular six-month treatment, patients with the strain have to take second-line medicines for more than 20 months.

Ninety per cent of the 62 patients interviewed for the study had good general knowledge about the disease. However, only 52.3 per cent were aware of adverse drug reactions or the fact that they can be managed or prevented. Forty-three per cent of the patients believed the reactions were not caused by drugs meant to fight TB.

Patients who are malnourished, have a history of alcoholism, a pre-existing condition and poor kidney or live function are more prone to experiencing adverse reactions. The guidelines of the World Health Organization recommend regular monitoring and documentation for identification and management of the effects.

The study was conducted by Dr Jaya Bajpai, Dr Rajendra Nanavare, Dr Jagdish Keni, Dr Deepa Arora, Dr Daksha Shah, and Dr Nilima A Kshirsagar.

  • Related Posts

    • Pharma
    • July 22, 2025
    • 112 views
    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    The Directorate General of Foreign Trade ( DGFT ) has notified an extension in the deadline for submitting applications for the export of Pharma Grade Sugar. This was communicated through Trade Notice…

    • Pharma
    • July 16, 2025
    • 539 views
    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Generic drugmakers Aurobindo Pharma, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir (CAB LA) for HIV treatment in 133 countries. This follows ViiV Healthcare, a company focused…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    10, 000 Km is just a Number for Intercontinental Tele Surgery by SSIMantra

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    DGFT Extends Deadline on Application for Export of Pharma Grade Sugar

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Bihar Healthcare is poised to be embraced by Robotic Surgery Mantra

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug

    Aurobindo, Cipla, Viatris to make, market long-acting injectable HIV drug